A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.
OBJECTIVE
To evaluate the efficacy and toxicity of gemcitabine and cisplatin combination chemotherapy, we conducted a phase II study of this regimen in patients with advanced non-small cell lung carcinoma (NSCLC).


METHODS
From June 2001 to August 2003, 36 chemotherapy-naive patients with stage IIIB or IV NSCLC were enrolled. The median age was 59 years (range, 42 to 75 years), and performance status was 0 or 1. Eleven patients had stage IIIB disease, and 25 patients had stage IV disease. 1,000 mg/m(2) of gemcitabine was administered on day 1 & 8, and 60 mg/m(2) of cisplatin was administered on day 1. Each cycle was repeated every 21 days.


RESULTS
Everyone subject who participated were assessable. A total of 160 cycles of chemotherapy were delivered, and the median number of chemotherapy courses was 3.5 (range, 2 to 9). Two patients (5.6%) achieved a complete response, and 14 patients (38.9%) achieved a partial response. The overall response rate was 44.5% (95% confidence interval [CI], 32.5 to 56.5%). The median follow-up duration was 9.3 months. The median time to disease progression was 8.6 months (95% CI 7.4 to 9.9 months), and median survival time was 12.2 months (95% CI, 10.5 to 12.9 months). Grade 3/4 neutropenia occurred in 9 patients (25.0%), neutropenic fever occurred in 3 patients (8.3%), and grade 3/4 thrombocytopenia occurred in 7 patients (19.5%). Mild forms of non-hematologic toxicities, such as nausea, vomiting or skin reactions, were observed.


CONCLUSIONS
The combination of gemcitabine and cisplatin in a 21-day schedule is an effective regimen for patients with NSCLC in its advanced stages.
Park
Jong-Sung
JS
Department of Internal Medicine, College of Medicine, Dong-A University, Dong-A Cancer Center, Busan, Korea.
Lee
Chang-Min
CM
Lee
Shin-Ae
SA
Jung
Chang-Kil
CK
Kim
Sung-Hyun
SH
Kwon
Hyuk-Chan
HC
Kim
Jae-Seok
JS
Kim
Hyo-Jin
HJ
Lung Cancer. 2000 Nov;30(2):117-25
11086205
Cancer Res. 1991 Nov 15;51(22):6110-7
1718594
J Clin Oncol. 1991 Mar;9(3):491-8
1999720
J Clin Oncol. 1997 Jan;15(1):297-303
8996156
Eur J Cancer. 1994;30A(3):417-8
8204374
Invest New Drugs. 1992 Aug;10(3):165-70
1428726
J Clin Oncol. 1999 Jan;17(1):12-8
10458212
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-18-S8-23
9207311
Semin Oncol. 1998 Aug;25(4 Suppl 9):35-43
9728583
J Clin Oncol. 2000 Feb;18(3):623-31
10653877
BMJ. 1995 Oct 7;311(7010):899-909
7580546
Ann Oncol. 2001 Sep;12(9):1221-30
11697832
Cancer Treat Rev. 1993 Jan;19(1):45-55
8431926
Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-27-S8-30
9207313
J Clin Oncol. 2003 Nov 1;21(21):3909-17
14581415
J Clin Oncol. 1994 Sep;12(9):1821-6
8083706
J Clin Oncol. 1994 Aug;12(8):1535-40
8040664
Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9
7481849
J Clin Oncol. 2002 Nov 1;20(21):4285-91
12409326
Bull Cancer. 1996 May;83(5):385-94
8680091
Cancer Res Treat. 2002 Feb;34(1):23-7
26680838
Anticancer Drugs. 1995 Dec;6 Suppl 6:33-7
8718423
Eur J Cancer. 1996 Feb;32A(2):243-8
8664035
J Clin Oncol. 1997 May;15(5):2097-102
9164223